Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and antitumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

被引：0

作者：

Olszanski, A. J. ^{[1
]}

Luke, J. J. ^{[2
]}

LoRusso, P. M. ^{[3
]}

Falchook, G. S. ^{[4
]}

Bedard, P. L. ^{[5
]}

Sanborn, R. E. ^{[6
]}

Patel, S. P. ^{[7
]}

Orr, D. ^{[8
]}

Gibbs, J. P. ^{[9
]}

Li, C. ^{[9
]}

Huang, Y-C. ^{[9
]}

Gregory, R. ^{[9
]}

Perera, S. ^{[9
]}

Xu, R. ^{[9
]}

Joshi, A. ^{[9
]}

Lee, M. Y. ^{[9
]}

Raizer, J. ^{[9
]}

Gao, X. ^{[10
]}

机构：

[1] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA

[2] Univ Pittsburgh, Canc Immunotherapeut Ctr, Med, Pittsburgh, PA USA

[3] Yale Canc Ctr, Med Oncol, New Haven, CT USA

[4] Sarah Cannon Res Inst SCRI HealthONE, Drug Dev Unit, Denver, CO USA

[5] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada

[6] Earle A Chiles Res Inst, Providence Canc Inst, Oncol, Portland, OR USA

[7] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA

[8] Mary Crowley Canc Res, Oncol, Dallas, TX USA

[9] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[10] Massachusetts Gen Hosp, Med, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1029P

引用

页码：S625 / S626

页数：2

共 50 条

[41] A phase I/II dose escalation and dose expansion study of ozuriftamab vedotin (BA3021) alone and in combination with nivolumab in patients with advanced solid tumors including non-small cell lung cancer
Alexander, M.
Starodub, A.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S84 - S84
[42] A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Krauss, J.
Eigentler, T.
Schreiber, J.
Weishaupt, C.
Terheyden, P.
Heinzerling, L.
Mohr, P.
Weide, B.
Ochsenreither, S.
Gutzmer, R.
Becker, J. C.
Kiecker, F.
Funkner, F.
Heidenreich, R.
Kays, S-K.
Klinkhardt, U.
Gnad-Vogt, U. S.
Scheel, B.
Schoenborn-Kellenberger, O.
Seibel, T.
ANNALS OF ONCOLOGY, 2019, 30 : 191 - +
[43] Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Mckean, M. A.
Lakhani, N. J.
Arkenau, H-T.
Symeonides, S.
Evans, T. R. J.
Lim, E. A.
Fontana, E.
Bupathi, M.
Mclaren, A.
Chandana, S. R.
Ding, T-E.
Rotolo, J.
Capiaux, G.
Michel, R.
Kaesshaefer, S.
Bexon, A.
Falchook, G. S.
ANNALS OF ONCOLOGY, 2021, 32 : S592 - S592
[44] A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors
Ma, Fei
Xu, Nong
Tang, Huoling
Zhou, Yuhong
Wei, Ziping
Munster, Pamela N.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Mettu, Niharika B.
Ulahannan, Susanna, V
Bendell, Johanna C.
Garrido-Laguna, Ignacio
Strickler, John H.
Moore, Kathleen N.
Stagg, Robert
Kapoun, Ann M.
Faoro, Leonardo
Sharma, Sunil
CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
[46] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
Ho, A. L.
Bendell, J. C.
Cleary, J. M.
Schwartz, G. K.
Burris, H. A.
Oakes, P.
Agbo, F.
Barker, P. N.
Senderowicz, A. M.
Shapiro, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[47] PHASE I DOSE ESCALATION STUDY OF THE SAFETY, IMMUNOREGULATORY ACTIVITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF NIVOLUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA IN PATIENTS WITH OR WITHOUT CHRONIC VIRAL HEPATITIS
Sangro, B.
El-Khoueiry, A. B.
Crocenzi, T. S.
Welling, T. H., III
Feely, W.
Anderson, J. A.
dela Cruz, C.
Melero, I.
JOURNAL OF HEPATOLOGY, 2015, 62 : S849 - S849
[48] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
Yamamoto, Noboru
Hafez, Navid
Tolcher, Anthony W.
Teufel, Michael
Geng, Junxian
Svensson, Liz
Lahmar, Mehdi
Gounder, Mrinal M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS
Eigentler, Thomas
Heinzerling, Lucie
Krauss, Juergen
Weishaupt, Carsten
Mohr, Peter
Ochsenreither, Sebastian
Terheyden, Patrick
Martin-Liberal, Juan
Oliva, Marc
Lebbe, Celeste
Fluck, Michael
Brossart, Peter
Trigo Perez, Jose Manuel
Bauernfeind, Franz-Georg
Kays, Sarah-Katharina
Seibel, Tobias
Schoenborn-Kellenberger, Oliver
Stosnach, Claudia
Daehling, Angelika
Schmitt-Bormann, Beate
Gnad-Vogt, Ulrike
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A478 - A479
[50] A PHASE I, DOSE ESCALATION AND EXPANSION STUDY OF PT199, A NEXT GENERATION CD73 MONOCLONAL ANTIBODY, ADMINISTERED ALONE AND IN COMBINATION WITH A PD-1 INHIBITOR IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Melhem, Ramzi
Wright, Harold
Zou, Hui
Ramos, Claudia
Li, Jack
Wang, Ming
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A811 - A811

← 1 2 3 4 5 →